Vitrakvi Approved
New Drug Approved for Patients with Rare Gene Fusion By Sara Rothschild, MPH, Vice President, Program Services & Jerry Call, Data Analyst The Food and Drug Administration granted accelerated approval on November 26th to [...]
Important Research Study Holds Hope for “Quadruple Wildtype” GIST Patients
A recent study published in the Journal of Translational Medicine, presents important research findings for the 10-15% of GIST patients who lack mutations in KIT, PDGFRA, SDHX or RAS pathway indicators, the primary oncogenic [...]
Loxo Oncology Announces Plans for LOXO-101
In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]
LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions
Loxo Oncology announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]
LOXO-101 Holds Promise as Potential Treatment Targeting Solid Tumors
A recent announcement from the University of Texas MD Anderson Cancer Center described a study that shows promise for a potential treatment (LOXO-101) that targets solid tumors with NTRK gene fusions. The investigational agent, [...]